We are live on
!
Find out more
OCA
Octagon Capital Advisors Portfolio holdings
AUM
$904M
1-Year Est. Return
737.04%
This Fund
S&P 500
This Quarter
Est. Return
+11.95%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$695M
AUM Growth
+$52.8M
(+8.2%)
Cap. Flow
+$69M
Cap. Flow
% of AUM
9.93%
Top 10 Holdings %
Top 10 Hldgs %
77.53%
Holding
46
New
14
Increased
8
Reduced
6
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Roivant Sciences
ROIV
|
+$32.1M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
+$21.7M |
| 3 |
Jasper Therapeutics
JSPR
|
+$11.8M |
| 4 |
Viridian Therapeutics
VRDN
|
+$11.6M |
| 5 |
Travere Therapeutics
TVTX
|
+$10.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$27.4M |
| 2 |
State Street SPDR S&P Biotech ETF
XBI
|
+$16.6M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$6.1M |
| 4 |
Arcus Biosciences
RCUS
|
+$5.94M |
| 5 |
Stoke Therapeutics
STOK
|
+$5.21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
| $214M | 30.84% |
3,250,000
+90,000
| +3% | +$5.19M |
|
|
KDNY
2
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $59.1M | 8.5% |
2,551,703
| – | – |
|
|
VRNA
3
DELISTED
Verona Pharma
VRNA
| $49.6M | 7.13% |
2,468,000
| – | – |
|
|
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
| $39.9M | 5.73% |
4,570,918
+2,711,718
| +146% | +$21.7M |
|
|
5
Arcus Biosciences
RCUS
$3.57B
| $39.6M | 5.7% |
2,172,000
-310,700
| -13% | -$5.94M |
|
|
6
Viridian Therapeutics
VRDN
$2.13B
| $30.1M | 4.34% |
1,185,000
+360,800
| +44% | +$11.6M |
|
|
7
Roivant Sciences
ROIV
$25.2B
| $28.8M | 4.15% |
+3,904,000
| New | +$32.1M |
|
|
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $27.9M | 4.01% |
750,000
| – | – |
|
9
Celldex Therapeutics
CLDX
$2.77B
| $27.3M | 3.93% |
759,898
-1,500
| -0.2% | -$64.7K |
|
10
BridgeBio Pharma
BBIO
$16.5B
| $22.2M | 3.19% |
1,338,160
+404,417
| +43% | +$4.72M |
|
11
Tandem Diabetes Care
TNDM
$1.17B
| $19.3M | 2.78% |
474,929
| – | – |
|
|
JBIO
12
Jade Biosciences
JBIO
$1.22B
| $12.5M | 1.8% |
17,763
| – | – |
|
|
13
Jasper Therapeutics
JSPR
$22.9M
| $11.6M | 1.66% |
+638,250
| New | +$11.8M |
|
|
14
Travere Therapeutics
TVTX
$5.33B
| $11.1M | 1.6% |
+495,000
| New | +$10.5M |
|
|
ALPN
15
DELISTED
Alpine Immune Sciences Inc
ALPN
| $9.28M | 1.34% |
1,202,000
-23,000
| -2% | -$183K |
|
16
4D Molecular Therapeutics
FDMT
$526M
| $8.59M | 1.24% |
499,996
| – | – |
|
|
ITOS
17
DELISTED
iTeos Therapeutics
ITOS
| $8.11M | 1.17% |
596,000
+151,000
| +34% | +$2.71M |
|
18
Dyne Therapeutics
DYN
$4.04B
| $7.98M | 1.15% |
+692,945
| New | +$9M |
|
19
Xilio Therapeutics
XLO
$56.9M
| $7.69M | 1.11% |
173,214
| – | – |
|
20
Viking Therapeutics
VKTX
$4.04B
| $6.24M | 0.9% |
375,000
-495,500
| -57% | -$5.12M |
|
21
Vera Therapeutics
VERA
$2.54B
| $6.17M | 0.89% |
795,000
+129,844
| +20% | +$1M |
|
|
ETNB
22
DELISTED
89bio
ETNB
| $6.09M | 0.88% |
400,000
+20,000
| +5% | +$261K |
|
|
RNAM
23
DELISTED
Avidity Biosciences
RNAM
| $5.86M | 0.84% |
382,000
+57,371
| +18% | +$1.26M |
|
|
ITCI
24
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $5.13M | 0.74% |
94,700
-126,253
| -57% | -$6.1M |
|
25
Geron
GERN
$911M
| $4.94M | 0.71% |
+2,278,000
| New | +$6.47M |
|
Similar funds
AIC
AOWM
SWM
EI
PIP
PSCM
EWM
PC
Octagon Capital Advisors's Q1 2023 Portfolio in Review
As of Q1 2023, Octagon Capital Advisors held 46 positions worth $695M, up 8.2% from $642M the previous quarter. Its ten largest holdings account for 78% of the portfolio.
Octagon Capital Advisors deployed $69M of net new capital in Q1 2023, opening 14 new positions and adding to 8 existing holdings. Its largest new stake was Roivant Sciences: 3,904,000 shares worth $28.8M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.
On the sell side, the largest reduction was Intra-Cellular Therapies Inc., an estimated $6.1M trimmed.
- Octagon Capital Advisors's largest Q1 2023 buy was Roivant Sciences: 3,904,000 shares worth $28.8M.
- Octagon Capital Advisors added most to Cymabay Therapeutics in Q1 2023, an estimated $21.7M increase.
- Octagon Capital Advisors's biggest Q1 2023 reduction was Intra-Cellular Therapies Inc., cutting an estimated $6.1M.
- Octagon Capital Advisors fully exited IVERIC bio, Inc. Common Stock in Q1 2023, selling an estimated $27.4M.
- Octagon Capital Advisors's ten largest holdings make up 78% of its $695M portfolio in Q1 2023.
- Octagon Capital Advisors opened 14 new positions and closed 10 in Q1 2023.
- Octagon Capital Advisors's portfolio value rose 8.2% quarter-over-quarter to $695M.
Based on Octagon Capital Advisors's 13F filing for Q1 2023, filed 15 May 2023.